ir.windtreetx.com Open in urlscan Pro
2a02:26f0:e300::211:93e1  Public Scan

Form analysis
1 forms found in the DOM

GET https://windtreetx.com/

<form role="search" method="get" class="et-search-form" action="https://windtreetx.com/">
  <input type="search" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:">
</form>

Text Content

Skip to main navigation


HEADER NAV

 * Company
   * Company Overview
   * Management
   * Board of Directors
   * Corporate Governance
   * Contact Us
   * Diversity, Inclusion and Innovation
 * Pipeline and Technology
   * Pipeline and Therapeutic Overview
   * Istaroxime
   * SERCA2a Activators
   * Lucinactant (KL4 surfactant)
   * AEROSURF®
   * Rostafuroxin
   * Expanded Access Policy
 * Business Development
 * Investors
   * Welcome
   * Financial Information
     * IR Snapshot
     * Annual Reports
     * Analyst Coverage
   * Financial Fundamentals
   * Stock Information
     * Stock Quote & Chart
     * Historic Price Lookup
   * Filings
     * SEC Filings
     * Ownership
   * Corporate Governance
   * Corporate Presentation
   * Events
   * Press Releases
   * Investor Alerts
 * Contact Us

Select Page
 * Company
   * Company Overview
   * Management
   * Board of Directors
   * Corporate Governance
   * Contact Us
   * Diversity, Inclusion and Innovation
 * Pipeline and Technology
   * Pipeline and Therapeutic Overview
   * Istaroxime
   * SERCA2a Activators
   * Lucinactant (KL4 surfactant)
   * AEROSURF®
   * Rostafuroxin
   * Expanded Access Policy
 * Business Development
 * Investors
   * Welcome
   * Financial Information
     * IR Snapshot
     * Annual Reports
     * Analyst Coverage
   * Financial Fundamentals
   * Stock Information
     * Stock Quote & Chart
     * Historic Price Lookup
   * Filings
     * SEC Filings
     * Ownership
   * Corporate Governance
   * Corporate Presentation
   * Events
   * Press Releases
   * Investor Alerts
 * Contact Us




WELCOME


HEADER NAV

 * Welcome
 * Financial Information
   * IR Snapshot
   * Annual Reports
   * Analyst Coverage
 * Financial Fundamentals
 * Stock Information
   * Stock Quote & Chart
   * Historic Price Lookup
 * Filings
   * SEC Filings
   * Ownership
 * Corporate Governance
 * Corporate Presentation
 * Events
 * Press Releases
 * Investor Alerts


TOOLKIT

 * Email Alerts
 * Print Page
 * Share
 * RSS Feeds
 * Contact IR
 * Search


WELCOME

Windtree Therapeutics, Inc. is advancing late-stage interventions for
cardiovascular disorders to treat patients in moments of crisis.
Using new scientific and clinical approaches, Windtree is developing a
multi-asset franchise anchored around compounds with an ability to activate
SERCA2a, with our lead candidate, istaroxime, being developed as a first in
class treatment for cardiogenic shock and acute heart failure.

Our Focus: Istaroxime in Cardiogenic Shock
In May 2022, Windtree reported our positive Phase 2 study of istaroxime in early
cardiogenic shock (SEISMiC study) results. The study’s positive primary endpoint
and results have paved the way for our clinical development to potentially have
istaroxime Phase 3 ready for cardiogenic shock in 2024.
After these positive data results, Windtree has prioritized istaroxime in
cardiogenic shock as our focus. We made this decision based upon the data and
these drivers of opportunity and potential commercial value:

 * Currently available pharmacologic treatments for cardiogenic shock have poor
   outcomes and undesirable side effects
 * Lack of competition in development or in the market
 * Very high cost of cardiogenic shock care (~19.5 days1 in the hospital and >
   $200k cost2) which creates a big opportunity to demonstrate pharmacoeconomic
   benefits
 * Attractive valuation of commercial market potential versus time and cost of
   development

Cardiogenic shock is a severe presentation of heart failure characterized by low
blood pressure and inadequate blood flow to vital organs (hypoperfusion)
accompanied by congestion and high filling pressures of the heart. Cardiogenic
shock is an area of extreme unmet need with no satisfactory pharmacologic
interventions to reverse the condition and available therapies have unwanted
side effects such as arrythmias, decreasing blood pressure, renal dysfunction
and increases in mortality. Cardiogenic shock has high mortality (approximately
30-40%) and substantial morbidity in survivors.
There is potential for a relatively fast and less expensive development and
regulatory pathway for istaroxime.

Windtree’s Unique Approach with SERCA2a Activation
Windtree’s heart failure platform includes follow-on preclinical SERCA2a
Activator assets as well.

Dual mechanism SERCA2a Activators: This class of drug candidates have a similar
MOA to istaroxime. The first mechanism strengthens the contraction of the heart
and the second mechanism promotes the relaxation of the heart’s ventricles so
they can fill with more blood in between the heart beats. This group may be well
suited for study in both the hospital inpatient area for acute HF where it could
be administered as an IV and in the outpatient area as a potential oral pill
formulation after a patient is released from the hospital. This group could be
developed as a “fast follow on” to istaroxime in acute decompensated heart
failure but offer the potential benefit of chronic dosing following patient
hospital discharge.

Pure SERCA2a Activators: This group’s mechanism of action focuses on the
relaxation of the ventricles to fill more with blood in between heart beats. The
group may be well suited for study in chronic heart failure as an outpatient in
heart failure with preserved ejection fraction or HfpEF. This is an area highly
underserved in CV disease.

Also in its portfolio is rostafuroxin, a novel precision drug product targeting
treatment resistant hypertensive patients with certain genetic profiles.
AEROSURF and KL4 have been out-licensed globally to Lee’s Pharmaceutical (HK)
and Zhoake Pharmaceutical.

_______________________________________________________
1  US Hospital Claims Data, 2022
2 Agency for Healthcare Research and Quality (AHRQ), 2018

 


RECENT NEWS

May 7, 2024
Windtree Therapeutics Regains Compliance with Nasdaq
WARRINGTON, Pa. , May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.
(“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused
on advancing early and late-stage innovative therapies for critical conditions
and diseases, today announced it has received a Bid Price
Apr 18, 2024
Windtree Therapeutics Announces Reverse Stock Split
WARRINGTON, Pa. , April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.
(NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on
advancing early and late-stage innovative therapies for critical conditions,
today announced that the Company’s Board of Directors has
Apr 17, 2024
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
and Provides Key Business Updates
WARRINGTON, Pa. , April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.
(“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused
on advancing early and late-stage innovative therapies for critical conditions,
today reported financial results for the fourth quarter
 * Today
 * 3 mo.
 * 6 mo.
 * 1 year


TODAY


3 MO.


6 MO.


1 YEAR

NASDAQ: WINT
$3.64
0 (0.00%)
Volume:
461
Market Cap:
$2.15 M

Data Provided by Refinitiv. Minimum 15 minutes delayed.



© Copyright 2024 Windtree Therapeutics, Inc